• Home
  • Submit news
  • Advertise with us
  • Home
  • Submit news
  • Advertise with us
Converter News
  • Converting
  • Print News
  • Food
  • Packaging
  • Manufacturing
  • Paper
  • Plastic
  • Nonwovens
Menu
  • Converting
  • Print News
  • Food
  • Packaging
  • Manufacturing
  • Paper
  • Plastic
  • Nonwovens
loading...
BREAKING NEWS
  • Manhattan Associates partners with robotics companies, automation provider and consultant
  • DOE recognizes Better Buildings Initiative partners
  • Zebra Technologies to acquire Profitect Inc.
  • Merck acquires Peloton Therapeutics for $1 billion
  • Making the Case for Lift Truck/MRO, Maintain and sustain your operations
  • IBM delivers basics of blockchain for logistics
  • Essity Divests Stake in Turkish Buisness
  • Mallinckrodt sues US health agencies after Medicaid changes
  • I.D. Images appoints two new account executives
  • Weldon Celloplast to distribute TrojanLabel equipment in India
Home Pierre Fabre Receives Positive CHMP Opinion for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in Adult Patients with Advanced BRAF-Mutant Melanoma

Pierre Fabre Receives Positive CHMP Opinion for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in Adult Patients with Advanced BRAF-Mutant Melanoma

on: July 30, 2018In:
Print Email
Pierre Fabre today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of BRAFTOVI®...

Source: AZoM.com - Materials and Engineering News Feed
More...

Share 0
Tweet
Share
Share
Share
  • Previous

    Pyroelectric detectors for NO2 measurements

  • Next

    Safety can now pay its way!

Facebook